Polaryx Therapeutics, Inc. (PLYX)
Polaryx Therapeutics, Inc. (PLYX)
| Balance Sheets | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 3,080 | 5,143 | ||
| Prepaid expenses | 389 | - | ||
| Other current assets | 33 | 27 | ||
| Total current assets | 3,502 | 5,170 | ||
| Total assets | 3,502 | 5,170 | ||
| Accounts payable | 850 | 470 | ||
| Due to related party | 98 | 91 | ||
| Accrued expenses related party | 45 | 23 | ||
| Accrued expenses and other current liabilities | 21 | 21 | ||
| Total current liabilities | 1,014 | 605 | ||
| Total liabilities | 1,014 | 605 | ||
| Common stock 0.0001 par value 560,000,000 shares authorized 47,343,297 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 5 | 5 | ||
| Additional paid-in capital | 104,662 | 104,195 | ||
| Accumulated deficit | -102,179 | -99,635 | ||
| Total stockholders equity | 2,488 | 4,565 | ||
| Total liabilities and stockholders equity | 3,502 | 5,170 | ||